颅内或颅外动脉粥样硬化性狭窄分层下缺血性卒中后双联抗血小板治疗
该研究为随机临床试验亚组分析,纳入5664例急性轻型缺血性卒中或高危TIA患者,按症状性ICAS或ECAS状态分为四组。结果显示ICAS+ECAS组90天复发卒中风险最高(13.2%),但氯吡格雷联合阿司匹林与单用阿司匹林在四组间对复发卒中和中重度出血无显著交互作用。
要点
- ICAS+ECAS组90天复发卒中风险13.2%,高于无狭窄组5.7%、仅ICAS组7.2%和仅ECAS组10.3%。
- 双联抗血小板与单药阿司匹林在四组间对复发卒中和中重度出血无显著交互作用。
- 研究未发现抗血小板治疗与症状性ICAS或ECAS状态之间存在交互效应。
核心结论
- 急性轻型缺血性卒中或TIA患者中,ICAS+ECAS组复发卒中风险高于其他组,但抗血小板治疗与ICAS/ECAS状态对复发卒中和中重度出血无交互作用。
研究设计与样本
- 随机临床试验的亚组分析,纳入5664例急性轻型缺血性卒中或高危TIA患者,按症状性ICAS或ECAS状态分为ICAS+ECAS组、仅ECAS组、仅ICAS组和无狭窄组。
主要发现
- 90天复发卒中风险:无狭窄组5.7%,仅ICAS组7.2%,仅ECAS组10.3%,ICAS+ECAS组13.2%,p<0.001。
- 氯吡格雷联合阿司匹林较单用阿司匹林复发风险数值上更低,但四组间无显著治疗效应差异。
- 抗血小板治疗与症状性ICAS或ECAS状态对复发卒中和中重度出血无显著交互作用。
关键数值与推荐
- 主要疗效终点为90天内任何新发卒中,主要安全终点为90天内中重度出血。
临床怎么用
- 对于急性轻型缺血性卒中或TIA,ICAS+ECAS患者复发风险较高,但双联抗血小板治疗的获益未因ICAS/ECAS状态而显著不同。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This objective of this study was to assess the efficacy and safety of clopidogrel plus aspirin for acute mild stroke or high-risk transient ischemic attack (TIA) stratified by the status of symptomatic intracranial atherosclerotic stenosis (ICAS) or extracranial atherosclerotic stenosis (ECAS). METHODS: The study was a subgroup analysis of a randomized clinical trial. Participants with mild ischemic stroke or TIA were assigned to receive either clopidogrel plus aspirin or aspirin monotherapy. Participants were categorized into 4 groups by the status of symptomatic ICAS or ECAS: ICAS + ECAS group, only ECAS group, only ICAS group, and no stenosis group. The primary efficacy end point was any new stroke and the primary safety end point was moderate-to-severe bleeding within 90 days. RESULTS: The study enrolled 5,664 patients. Compared with other groups, the ICAS + ECAS group had a higher risk of recurrent stroke within 90 days (no stenosis = 5.7%; only ICAS = 7.2%; only ECAS = 10.3%; and ICAS + ECAS = 13.2%; p < 0.001). Although clopidogrel plus aspirin showed a numerically lower recurrence risk versus aspirin alone, no significant treatment effect difference emerged across the 4 groups. No significant interaction between antiplatelet therapy and the status of symptomatic ICAS or ECAS for recurrent stroke and moderate-to-severe bleeding was identified. INTERPRETATION: For acute mild ischemic stroke or TIA, although patients with both symptomatic ICAS and ECAS exhibited an elevated risk of recurrent stroke than other patients, no interaction effect between antiplatelet therapy and the status of symptomatic ICAS or ECAS for the risk of new stroke and moderate-to-severe bleeding was observed. ANN NEUROL 2026;99:429-436.
引用
- Yang Y, Yang J, Gao Y, et al. Dual Antiplatelet Therapy After Ischemic Stroke Stratified by Intracranial or Extracranial Atherosclerotic Stenosis. Ann Neurol. 2025. PMID: 40990347. doi:10.1002/ana.78049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。